In total there are 119 users online :: 26 registered, 0 hidden and 93 guests (based on users active over the past 150 minutes)
Most users ever online was 234 on Wed Dec 27, 2017 9:58 pm
Registered users: ADAM , admin , Aow88 , Ben15 , Bing [Bot] , Bullitt12345 , DarrenG , Deads4days , Google [Bot] , icecubes93 , Kentus1990 , Kompany4 , Kubis , learntofly , littlematt , lordfuzzball , MashasNurn , Mitchlowkey , NoGutsNoGlory , One rep max , P44ttf , Shay , Shrugss , Thomas , tricky , Viz
Legend: Administrators , Global moderators
However, in December 2004 the United States the 14-member Food and Drug Administration (FDA) advisory committee, plus voting consultants, for Reproductive Health Drugs unanimously rejected Procter and Gamble's fast-track request for Intrinsa citing concerns about off-label use . In Canada, post-menopausal women have been able to obtain government-approved testosterone treatment since 2002. In Australia, post-menopausal women can use Organon testosterone implants which have to be surgically inserted and last from three to six months. 
Dromostanolone is a synthetic androgenic anabolic steroid and is approximately 5 times as potent as natural methyltestosterone. Like testosterone and other androgenic hormones, dromostanolone binds to the androgen receptor. This causes downstream genetic transcriptional changes. This ultimately causes retention of nitrogen, potassium, and phosphorus; increases protein anabolism; and decreases amino acid catabolism. The antitumour activity of dromostanolone appears related to reduction or competitive inhibition of prolactin receptors or estrogen receptors or production.